For the Inventor, By the Inventor

Enter assignee name

Heidelberg, Germany

Novaliq Gmbh

Calculating rank

USPTO Granted Patents = 54

% Expired Patents = 1.9

CIPO Patents = 4

EPO Patents = 42

Trademarks = 7

Forward Citations = 1,012

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Bernhard Günther (30 out of 31 patents)

Sonja Theisinger (19 out of 20 patents)

Bastian Theisinger (19 out of 22 patents)

4. Dieter Scherer (18 out of 20 patents)

5. Frank Löscher (17 out of 21 patents)

6. Sonja Krösser (8 out of 8 patents)

7. Hartmut Voss (8 out of 9 patents)

8. Anthony Pettigrew (8 out of 8 patents)

9. Ralf Grillenberger (7 out of 10 patents)

10. Markus Beier (6 out of 27 patents)

11. Kirsten Eickhoff (6 out of 6 patents)

12. Thomas Schlüter (4 out of 5 patents)

13. Alice Meides (4 out of 4 patents)

14. Gesche Graf (4 out of 4 patents)

15. Clive G Wilson (4 out of 5 patents)

Core Competencies:

Ocular Neovascularization

Dry Eye Disease

Glaucoma Treatment

Semifluorinated Alkanes

Ciclosporin

Timolol

Uveitis Treatment

Increased Intraocular Pressure

Topical Administration

Pharmaceutical Compositions

Stabilized Antibody Compositions

Liquid Pharmaceutical Composition

54 patents: Sort by Forward Citations

1. 12774996 - Methods of analyzing liquid pharmaceutical compositions (2026-10-27),

2. 12766183 - Ophthalmic composition for treatment of dry eye disease (2026-10-20),

3. 12599607 - Pharmaceutical compositions comprising timolol (2026-04-14),

4. 12569452 - Ophthalmic compositions comprising F6H8 (2026-03-10),

5. 12496326 - Ophthalmic composition for treatment of dry eye disease (2025-12-16),

6. 12419933 - Ophthalmic composition for the treatment of uveitis (2025-09-23),

7. 12397039 - Compositions and methods for the treatment of ocular neovascularization (2025-08-26),

8. 12310977 - Use of semi-fluorinated alkanes in transdermal therapeutic systems (2025-05-27),

9. 12226422 - Ophthalmic compositions comprising tafluprost for the treatment of glaucoma (2025-02-18),

10. 12128010 - Semifluorinated compounds and their compositions (2024-10-29),

11. 12059449 - Ophthalmic composition for treatment of dry eye disease (2024-08-13),

12. RE50060 - Topical administration method (2024-07-30),

13. 12005033 - Compositions comprising mixtures of semifluorinated alkanes (2024-06-11),

14. 11987623 - Stabilized antibody compositions (2024-05-21),

15. 11896559 - Opthalmic compositions comprising F6H8 (2024-02-13),

Company Overview

Novaliq GmbH, based in Heidelberg, Germany, specializes in innovative ophthalmic compositions aimed at addressing various eye conditions. The company focuses on developing treatments for ocular neovascularization, dry eye disease, and glaucoma, utilizing advanced technologies such as semifluorinated alkanes. Their research includes formulations incorporating ciclosporin and timolol, targeting uveitis and managing increased intraocular pressure. Novaliq is committed to enhancing patient care through cutting-edge solutions in ophthalmology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

54 Patents

#8 in Heidelberg

#990 in Germany

#13,146 in the World

Heidelberg, Germany

Novaliq Gmbh

Forward Citations = 1,012

40 inventors:

Bernhard Günther (30 out of 31 patents)

Sonja Theisinger (19 out of 20 patents)

Bastian Theisinger (19 out of 22 patents)

4. Dieter Scherer (18 out of 20 patents)

5. Frank Löscher (17 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novaliq Gmbh. Retrieved from https://idiyas.com/company/novaliq

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…